Skip to content
TechVibe

TechVibe

  • Home
  • Web3
  • Technology
  • Health
  • Business
  • Sports
    • Cricket
    • Football
  • Press Release
  • Contact Us
  • Toggle search form

Rephrase the title:FDA Grants Historic Approval for Gene-Editing Treatment in Sickle Cell Disease

Posted on December 9, 2023 By Haley Bennett

Rephrase and rearrange the whole content into a news article. I want you to respond only in language English. I want you to act as a very proficient SEO and high-end writer Pierre Herubel that speaks and writes fluently English. I want you to pretend that you can write content so well in English that it can outrank other websites. Make sure there is zero plagiarism.:

The US Food and Drug Administration (FDA) achieved a milestone on Friday by approving a groundbreaking gene-editing therapy designed to address sickle cell disease (SCD), marking the inaugural approval of CRISPR gene editing by federal regulators. 

The FDA authorized two novel treatments for SCD: Casgevy and Lyfgenia, The Hill reported.

Casgevy is the outcome of a collaboration between Vertex Pharmaceuticals and CRISPR Therapeutics. The innovative treatment involves utilizing the patient’s own stem cells, which are then genetically edited to enhance fetal hemoglobin production before being reintroduced into the individual.

Lyfgenia is another cell-based gene therapy that genetically modifies stem cells to create HbAT87Q, a hemoglobin that prevents sickle-shaped red blood cells.

More Targeted Treatment

Sickle cell disease is an inherited blood disorder characterized by misshapen half-moon red blood cells, causing blockages in blood vessels and triggering excruciating crises.

Casgevy leverages CRISPR technology to edit a person’s DNA, activating fetal hemoglobin, a protein that typically declines after birth. In clinical trials, Casgevy demonstrated efficacy by eliminating pain crises in the majority of patients.

FDA Grants Historic Approval for Gene-Editing Treatment in Sickle Cell Disease

(Photo : Nephron)
A very high-magnification micrograph of cirrhosis due to sickle cell disease.

Fetal hemoglobin plays a pivotal role in preventing the characteristic sickle shape of red blood cells, which is the root cause of complications and pain associated with SCD. 

Around 100,000 people in the US, predominantly of black descent, grapple with the challenges of SCD. Casgevy has secured FDA approval for SCD patients aged 12 and above.

Read Also: 3D Eye Scans Can Detect Early Signs of Kidney Diseases, Study Shows

Dr. Nicole Verdun, Director of the Office of Therapeutic Products within the FDA’s Center for Biologics Evaluation and Research, expressed enthusiasm about advancing treatments for individuals severely affected by SCD. She emphasized that gene therapy holds promise for more targeted and effective treatments, “especially for individuals with rare diseases where the current treatment options are limited,” according to CNBC.

While Casgevy is administered only once, the entire process spans months. Blood stem cells are extracted, genetically modified in Vertex’s lab, and then reintroduced into patients after chemotherapy. The recovery process involves spending weeks in the hospital.

Pricing Concerns

Vertex estimates that approximately 16,000 people with severe cases of sickle cell disease will be eligible for the treatment. However, despite its potential, analysts express concerns about the treatment’s complexity, the risk of infertility, and its potential cost barriers. 

The firm has set the price of the SCD treatment at $2.2 million per patient. Due to the intricate procedure, its administration will be limited to specific health facilities, such as academic medical centers. Nine healthcare facilities are prepared to commence the Casgevy administration, with additional facilities anticipated to join in the coming weeks.

Jennifer Doudna of the University of California, Berkeley, a pivotal figure in the discovery of CRISPR gene editing, is actively working to simplify gene-editing treatments. Biotech companies involved in these treatments are collaborating with private and public insurers to facilitate coverage. Advocates highlight potential cost savings compared to a lifetime of sickle cell complications.

While celebrating the groundbreaking approval, there are concerns about potential long-term effects and “off-target” errors in the DNA. For 15 years, the firms will track all treated individuals to evaluate the gene-editing SCD treatment’s durability, lifetime, and long-term problems, as reported by NPR.

Related Article: Biden Administration Facing Backlash as Menthol Cigarette Ban Delayed Again

byline quincy

ⓒ 2023 TECHTIMES.com All rights reserved. Do not reproduce without permission.

Haley Bennett

I have over 10 years of experience in the cryptocurrency industry and I have been on the list of the top authors on LinkedIn for the past 5 years. I have a wealth of knowledge to share with my readers, and my goal is to help them navigate the ever-changing world of cryptocurrencies.

Health Tags:fda, Genetics, health, Medicine, Sickle cell disease, Technology, U.S. Food and Drug Administration, United States

Post navigation

Previous Post: Rephrase the title:Infinix SMART 8 HD Debuts In India With iPhone 15 Pro Design And Dynamic Island Notch; Price, Specs
Next Post: Rephrase the title:India W vs England W 2nd T20I: TV channel, telecast and live stream details

Related Posts

CDC Raises Alarm on Increase in COVID-19, Flu, and RSV Cases Throughout the US Health
Rephrase the title:Russian Hackers Allegedly Behind Sweden Ransomware Attack Health
Rephrase the title:Apple Car’s Wake: New Report Details Deal with Mercedes, Ford, Tesla, and Steve Job’s Plan Health
Rephrase the title:Radia WindRunner: World’s Largest Plane is Twice the Size of Lady Liberty, Carries More Cargo Than Boeing 747 Health
Report from Congress: Chinese Companies Obtain American Machinery for Producing Advanced Chips Despite Export Restrictions Health
Rephrase the title:Coming Soon: Google Maps’ Immersive View Update Unveils Mind-Blowing ‘Multidimensional Experience’ Health

Recent Posts

  • Robin Open Social-Fi: Revolutionizes Gaming with Innovative Integration and Global Partnerships
  • $GUMMY Set to Launch New Meta On Staking on Solana
  • BinoStake.io: Transforming Crypto Investments On BNB Chain with Liquid Staking Solutions
  • Mocaverse to Develop Decentralized Social Layer
  • Expansion of Web3 Fueled by Hong Kong’s Financial Secretary

Categories

  • Business
  • Cricket
  • Football
  • Health
  • Press Release
  • Technology
  • Web3

About Us

Welcome to TechVibe9, where the rhythm of technology meets innovation! We are a group of tech enthusiasts on a mission to uncover and showcase the latest in the tech world.

Mail Us : support@techvibe9.com

Latest Post

  • Robin Open Social-Fi: Revolutionizes Gaming with Innovative Integration and Global Partnerships
  • $GUMMY Set to Launch New Meta On Staking on Solana
  • BinoStake.io: Transforming Crypto Investments On BNB Chain with Liquid Staking Solutions

Helpful Links

  • About Us
  • Contact Us
  • Privacy Policy
  • Terms & Conditions

Copyright © TechVibe9

Powered by PressBook Masonry Dark